Electra Therapeutics (ETRA) closed at $7.80 on November 6, 2026, up 6.1% from the previous close, on volume of 398,314 shares (30-day average 448,527).
Data as of November 6, 2026.
No headlines found.
Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
Business Wire (Fri, 23-Oct 7:00 AM ET)
Electra Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's pipeline includes Ipsoprubart and ELA822.
Electra Therapeutics trades on the NASDAQ stock market under the symbol ETRA.
As of November 6, 2026, ETRA stock price climbed to $7.80 with 398,314 million shares trading.
ETRA has a market cap of $489.58 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ETRA belongs to (by Net Assets): VTI, VXF, VTWO, VTWG, VTWV.
ETRA support price is $6.88 and resistance is $7.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ETRA shares will trade within this expected range on the day.
